proxyvotesnow.com

Home › Companies › Tango Therapeutics, Inc. › 2025-2026

Tango Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 6Reported items
  • 206Asset managers
  • 1,114Fund votes
  • 2026-06-04Meeting date

Proxy season: 2024-2025 2025-2026

Explore Tango Therapeutics, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the Tango Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 206 asset managers that disclosed a Tango Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Tango Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 200 asset managers below cast 99% of the shares they voted on this item FOR (120,049,149 for, 1,552,382 against).

FOR: 120,049,149 (98.7%)AGAINST: 1,552,382 (1.3%)ABSTAIN: 2,983 (0.0%)
Largest asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP13,300,6200 00For
Fidelity11,124,7690 00For
Boxer Capital Management, LLC9,329,7230 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.7,375,5770 00For
Woodline Partners LP6,611,0440 00For
TRV GP IV, LLC6,374,5740 00For
Siren, L.L.C.5,674,7580 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.5,046,0600 00For
BlackRock4,302,333286 00For
Janus Henderson4,217,9460 00For
DEERFIELD MANAGEMENT COMPANY, L.P.4,146,8130 00For
Vanguard3,671,3191 00For
State Street3,499,3321,315 00For
Deep Track Capital, LP2,750,0000 00For
Logos Global Management LP2,185,0630 00For
Vivo Capital, LLC2,154,7800 00For
Holocene Advisors, LP2,148,7470 00For
T. Rowe Price2,118,6240 00For
GEODE CAPITAL MANAGEMENT, LLC1,844,6520 00For
Paradigm Biocapital Advisors LP1,781,5240 00For
Caligan Partners LP1,777,4330 00For
Charles Schwab1,678,2640 00For
Candriam S.C.A.01,269,246 00Against
FRANKLIN ADVISERS INC1,148,4030 00For
PERCEPTIVE ADVISORS LLC1,118,5770 00For

Showing the 25 largest of 200 asset managers. See all 200 in the interactive database.

2. Election of Class II Directors: Malte Peters, M.D.

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 95%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (15,215,951 for, 0 against).

FOR: 15,215,951 (95.4%)ABSTAIN: 741,018 (4.6%)
Largest asset managers voting on “Election of Class II Directors: Malte Peters, M.D.” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,122,5440 00For
Vanguard2,969,8550 3,0650For
State Street2,324,6360 5,6870For
BlackRock2,116,8290 00For
Charles Schwab839,1000 00For
T. Rowe Price752,2950 00For
FRANKLIN STRATEGIC SERIES375,4350 00For
TIAA00 334,2980Abstain
QUANTITATIVE MASTER SERIES LLC174,4500 00For
Equitable102,8150 00For
SEI74,8900 00For
Lincoln Financial71,7000 00For
ProShares00 69,4230Abstain
Goldman Sachs54,8080 00For
AIG/SunAmerica00 52,1550Abstain
Global X51,8780 00For
Bridge Builder Trust49,6740 00For
Victory Capital00 48,5290Abstain
Putnam00 38,0360Abstain
Invesco00 35,4990Abstain
Jackson National21,0740 6,7340For
Voya00 27,2420Abstain
John Hancock15,4000 10,0560For
AQR00 24,6810Abstain
MFS22,7620 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. Election of Class II Directors: Kanishka Pothula

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 89%11%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (14,221,242 for, 0 against).

FOR: 14,221,242 (89.1%)ABSTAIN: 1,735,727 (10.9%)
Largest asset managers voting on “Election of Class II Directors: Kanishka Pothula” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,122,5440 00For
Vanguard2,971,4250 1,4950For
State Street2,327,6310 2,6920For
BlackRock2,116,8290 00For
Charles Schwab00 839,1000Abstain
T. Rowe Price752,2950 00For
FRANKLIN STRATEGIC SERIES00 375,4350Abstain
TIAA334,2980 00For
QUANTITATIVE MASTER SERIES LLC174,4500 00For
Equitable102,8150 00For
SEI00 74,8900Abstain
Lincoln Financial71,7000 00For
ProShares00 69,4230Abstain
Goldman Sachs54,8080 00For
AIG/SunAmerica00 52,1550Abstain
Global X00 51,8780Abstain
Bridge Builder Trust49,6740 00For
Victory Capital00 48,5290Abstain
Putnam00 38,0360Abstain
Invesco35,4990 00For
Jackson National21,0740 6,7340For
Voya27,2420 00For
John Hancock15,4000 10,0560For
AQR00 24,6810Abstain
MFS00 22,7620Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. Election of Class II Directors: Mace Rothenberg, M.D.

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 80%ABSTAIN 20%

The 50 asset managers below cast 100% of the shares they voted on this item FOR (12,738,254 for, 0 against).

FOR: 12,738,254 (79.8%)ABSTAIN: 3,218,714 (20.2%)
Largest asset managers voting on “Election of Class II Directors: Mace Rothenberg, M.D.” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,122,5440 00For
Vanguard2,968,3740 4,5460For
State Street1,8600 2,328,4630Abstain
BlackRock2,116,8290 00For
Charles Schwab839,1000 00For
T. Rowe Price752,2950 00For
FRANKLIN STRATEGIC SERIES375,4350 00For
TIAA00 334,2980Abstain
QUANTITATIVE MASTER SERIES LLC174,4500 00For
Equitable21,8150 81,0000Abstain
SEI74,8900 00For
Lincoln Financial00 71,7000Abstain
ProShares00 69,4230Abstain
Goldman Sachs54,8080 00For
AIG/SunAmerica00 52,1550Abstain
Global X51,8780 00For
Bridge Builder Trust49,6740 00For
Victory Capital00 48,5290Abstain
Putnam00 38,0360Abstain
Invesco35,4990 00For
Jackson National21,0740 6,7340For
Voya00 27,2420Abstain
John Hancock15,4000 10,0560For
AQR00 24,6810Abstain
MFS00 22,7620Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (15,956,885 for, 84 against).

FOR: 15,956,885 (100.0%)AGAINST: 84 (0.0%)
Largest asset managers voting on “To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity5,122,5440 00For
Vanguard2,972,9200 00For
State Street2,330,23984 00For
BlackRock2,116,8290 00For
Charles Schwab839,1000 00For
T. Rowe Price752,2950 00For
FRANKLIN STRATEGIC SERIES375,4350 00For
TIAA334,2980 00For
QUANTITATIVE MASTER SERIES LLC174,4500 00For
Equitable102,8150 00For
SEI74,8900 00For
Lincoln Financial71,7000 00For
ProShares69,4230 00For
Goldman Sachs54,8080 00For
AIG/SunAmerica52,1550 00For
Global X51,8780 00For
Bridge Builder Trust49,6740 00For
Victory Capital48,5290 00For
Putnam38,0360 00For
Invesco35,4990 00For
Jackson National27,8080 00For
Voya27,2420 00For
John Hancock25,4560 00For
AQR24,6810 00For
MFS22,7620 00For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 86%ABSTAIN 14%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (75,017 for, 0 against).

FOR: 75,017 (85.7%)ABSTAIN: 12,557 (14.3%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Tango Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
ALGERT GLOBAL LLC70,9500 00For
MANGROVE PARTNERS IM, LLC00 12,5570Abstain
APG Asset Management US Inc.2,4450 00For
ANTIPODES PARTNERS Ltd1,6220 00For

Largest Tango Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Tango Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 144,162,543 shares outstanding at the time of that meeting.

Top Tango Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 9.23%
2Fidelity 7.72%
3Boxer Capital Management, LLC 6.47%
4FARALLON CAPITAL MANAGEMENT, L.L.C. 5.12%
5Woodline Partners LP 4.59%
6TRV GP IV, LLC 4.42%
7Siren, L.L.C. 3.94%
8ADAGE CAPITAL PARTNERS GP, L.L.C. 3.50%
9BlackRock 2.98%
10Janus Henderson 2.93%

Reported Tango Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Tango Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Farallon Capital Management, L.L.C. 11.29% 13G
TCG Crossover II 9.38% DEF14A
RTW Investments, LP 9.23% 13G
Adage Capital Management, L.P. 7.36% DEF14A
TCG Crossover GP II, LLC 7.04% 13G
FMR (Fidelity) 6.87% 13F
BlackRock 6.07% 13F
Entities affiliated with Blackrock, Inc. 5.88% DEF14A
Vanguard Group 4.68% 13F
Third Rock Ventures IV, L.P. 4.42% 13D

Percentages above are of 144,162,543 shares outstanding, as reported by Tango Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tango Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Tango Therapeutics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 206 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,114 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Tango Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).